CN103263513A - Application of traditional Chinese medicine in preparation of drugs for paranoid psychosis - Google Patents
Application of traditional Chinese medicine in preparation of drugs for paranoid psychosis Download PDFInfo
- Publication number
- CN103263513A CN103263513A CN201310193209XA CN201310193209A CN103263513A CN 103263513 A CN103263513 A CN 103263513A CN 201310193209X A CN201310193209X A CN 201310193209XA CN 201310193209 A CN201310193209 A CN 201310193209A CN 103263513 A CN103263513 A CN 103263513A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- medicine
- traditional chinese
- grams
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to application of a traditional Chinese medicine in preparation of drugs for paranoid schizophrenia. The traditional Chinese medicine is prepared from the following active pharmaceutical ingredients in parts by weight: 10-16 parts of fructus psoraleae, 6-9 parts of asarum, 5-8 parts of peach kernel, 2-5 parts of fructus aurantii and 2-5 parts of fermented soybean. The invention adopts the pure natural traditional Chinese medicine raw materials, and the whole formula conforms to the 'monarch, minister, assistant and guide' principle of traditional Chinese medicines. The clinical test for years proves that the medicine has favorable effects of activating blood circulation to dissipate blood stasis, promoting the circulation of qi and relieving the depressed liver, has definite curative effect on schizophrenia, and has the advantages of fewer types of drugs, low toxic or side effect and no obvious adverse reaction. The effective ingredients of the medicine can be easily released and quickly absorbed, and the drug effect can be easily displayed. The medicine is convenient to carry, easy to take and beneficial to large-scale production, and thus, is a safe and effective medicine.
Description
Technical field
The present invention relates to a kind of application of Chinese medicine, specifically, is about the application of a kind of Chinese medicine in preparation Paranoid psychosis medicine.
Background technology
Schizophrenia (schizophrenia) is a kind of common psychosis, estimates according to World Health Organization (WHO), and the schizoid lifelong prevalence in the whole world probably is 3.8 ‰-8.4 ‰, the research of the U.S., and lifelong prevalence is up to 13 ‰; China's survey data in 1994, urban area prevalence 7.11 ‰, rural area 4.26 ‰.Schizophrenia cause of disease complexity, still illustrate fully at the end.A lot of diseases show as many-sided obstacles such as perception, thinking, emotion, volitional behavior in person between twenty and fifty, and ergasia and surrounding and inner experience are inharmonious, are divorced from reality.General unconscious obstacle and tangible disturbance of intelligence can have attention, working memory, abstract thinking and aspect Cognitive function damage such as information integrated.The course of disease is delayed more, outbreak repeatedly, and the ergasia decline takes place part patient and social function is damaged in various degree.Schizophrenia has following type: one, and intolerance style is main clinical manifestation with the vain hope, usually with hallucination., delusion of relation suspicious with sensitivity, delusion of persecution are seen more.Secondly be influence, envy etc.Several vain hopes of most humans exist simultaneously.Two, hebephrenictype is in the adolescence onset, and performance is excited, words are many, activity is many, gibberish, and behavior is strange, mixed and disorderly, unwise, inmature, and thinking, emotion and behavior are inharmonious.Three, catatonic type catatonic stupor and catatonic excitement are main clinical manifestation with the stress syndrome.Four, simple type is main clinical phase with the poverty of thought, apathy, aboulia, social negative symptoms such as shrink back.Insidious onset, slowly development, the course of disease at least two years, and tend to mental deterioration gradually.The positive symptom such as general no hallucination vain hope.
Summary of the invention
The objective of the invention is at deficiency of the prior art, provide a kind of Chinese medicine to use.
For achieving the above object, the technical scheme that the present invention takes is: the application of a kind of Chinese medicine in preparation treatment paranoid schizophrenia medicine, described Chinese medicine is to be made by following bulk drugs: Fructus Psoraleae 10-16 part, Herba Asari 6-9 part, Semen Persicae 5-8 part, Fructus Aurantii 2-5 part, Semen Sojae Preparatum 2-5 part.
Described Chinese medicine is to be made by following bulk drugs: 13 parts of Fructus Psoraleaes, 8 parts of Herba Asaris, 6 parts in Semen Persicae, 3 parts of Fructus Aurantiis, 3 parts of Semen Sojae Preparatums.
The invention has the advantages that: the present invention selects the natural Chinese medicines raw material for use, and full side's compatibility meets Chinese medicine " monarch " principle, verifies through clinical trial for many years; effect with good blood circulation promoting and blood stasis dispelling, promoting QI circulation for relieving depression, to the schizophrenia determined curative effect, the flavour of a drug number is less; toxic and side effects is little, and not seeing has obvious adverse reaction, and effective ingredient discharges easily; absorb fast; drug effect is not fully exerted easily, is easy to carry, and is easy to take; being beneficial to large-scale production, is a kind of safe and effective medicine.
The specific embodiment
Below the specific embodiment provided by the invention is elaborated.
Embodiment 1
Chinese medicine preparation (one)
Fructus Psoraleae 13 grams, Herba Asari 8 grams, Semen Persicae 6 grams, Fructus Aurantii 3 grams, Semen Sojae Preparatum 3 grams, the manufacture method by the Chinese medicine decoction routine decocts with water, and packing is standby.
Embodiment 2
Chinese medicine preparation (two)
Fructus Psoraleae 10 grams, Herba Asari 8 grams, Semen Persicae 8 grams, Fructus Aurantii 4 grams, Semen Sojae Preparatum 4 grams, the manufacture method by the Chinese medicine decoction routine decocts with water, and packing is standby.
Embodiment 3
Chinese medicine preparation (three)
Fructus Psoraleae 13 grams, Herba Asari 6 grams, Semen Persicae 5 grams, Fructus Aurantii 2 grams, Semen Sojae Preparatum 5 grams, the manufacture method by the Chinese medicine decoction routine decocts with water, and packing is standby.
Embodiment 4
Chinese medicine preparation (four)
Fructus Psoraleae 16 grams, Herba Asari 8 grams, Semen Persicae 5 grams, Fructus Aurantii 5 grams, Semen Sojae Preparatum 2 grams, the manufacture method by the Chinese medicine decoction routine decocts with water, and packing is standby.
Embodiment 5
Chinese medicine preparation (five)
Fructus Psoraleae 10 grams, Herba Asari 6 grams, Semen Persicae 5 grams, Fructus Aurantii 2 grams, Semen Sojae Preparatum 3 grams, the manufacture method by the Chinese medicine decoction routine decocts with water, and packing is standby.
Embodiment 6
Chinese medicine preparation (six)
Fructus Psoraleae 16 grams, Herba Asari 9 grams, Semen Persicae 8 grams, Fructus Aurantii 3 grams, Semen Sojae Preparatum 2 grams, the manufacture method by the Chinese medicine decoction routine decocts with water, and packing is standby.
Embodiment 7
Clinical experiment
1. experiment material
Matched group: rhizoma sparganic, Rhizoma Curcumae, Semen Persicae, Flos Carthami, Radix Bupleuri, Pericarpium Citri Reticulatae Viride, Radix Paeoniae Rubra, Radix Et Rhizoma Rhei, Herba Artemisiae Anomalae, Radix Gentianae (preparation method: rhizoma sparganic 6 grams, Rhizoma Curcumae 6 grams, Semen Persicae 1.5 grams, Flos Carthami 1.5 grams, Radix Bupleuri 1.5 grams, Pericarpium Citri Reticulatae Viride 1.5 grams, Radix Paeoniae Rubra 1.5 grams, Radix Et Rhizoma Rhei 3 grams, Herba Artemisiae Anomalae 3 grams, Radix Gentianae 1.5 grams are by the manufacture method of Chinese medicine decoction routine, decoct with water, packing is standby);
Of the present invention group: (adopting embodiment 1 to prepare).
2. clinical data
(1) includes standard in
All compound Chinese mental disorder classification of cases and diagnostic criteria the 3rd edition (CCMD-3), and＞40 parts of brief psychiatric rating scale (BPRS) scorings, body and lab testing were normal when the patient went into to organize.Eliminating has serious passive suicidal idea person and alcohol dependence person with serious physical disease person.
(2) physical data
Include 60 routine schizophrenia patients (intolerance style, hebephrenictype, catatonic type and simple type) altogether in by above-mentioned condition, be divided into matched group 30 examples at random by the prescription on individual diagnosis sequencing, of the present invention group of 30 examples.Two groups of patient's physical data compare there was no significant difference (P＞0.05).
3. experimental technique
Matched group: contrast prescription therapeutic, be decocted in water for oral dose 1 dose of every day, divide clothes 2 times, 4 weeks were 1 course for the treatment of, totally 2 courses for the treatment of.
Of the present invention group: give side's treatment of the present invention, be decocted in water for oral dose 1 dose of every day, divide clothes 2 times, 4 weeks were 1 course for the treatment of, totally 2 courses for the treatment of.
Observation index: in 4,8 whens week, adopted BPRS evaluation curative effect of medication before medication and after the medication, evaluates untoward reaction with TESS, and calculate the branch rate that subtracts of BPRS scoring, subtracts branch rate=(total points before the treatment-treatment back total points)/preceding total points for the treatment of * 100%.
Statistical procedures: experimental data represents that with x ± s one factor analysis of variance relatively with the t check, is relatively used in front and back in the group between group, and used statistical software is SPSS10.0.
(1) efficacy assessment standard
The branch rate that subtracts evaluation curative effect according to the BPRS scoring for the treatment of back.
Recovery from illness: BPRS subtracts branch rate 〉=80%, and mental symptom disappears;
Produce effects: BPRS subtracts branch rate 51-79%, and mental symptom obviously alleviates;
Take a turn for the better: BPRS subtracts branch rate 25-50%, and mental symptom alleviates;
Invalid: BPRS subtracts branch rate＜25% or sb.'s illness took a turn for the worse, cure-remarkable-effectiveness rate=cure rate+obvious effective rate.
(2) result
Experimental result: see Table 1, table 1 is that two groups of schizoid curative effects of Drug therapy compare.By table 1 data as seen, matched group 30 examples, 21 examples of fully recovering, produce effects 4 examples, 5 examples that take a turn for the better, invalid 0 example, cure-remarkable-effectiveness rate 83.3%; Of the present invention group of 30 examples, 28 examples of fully recovering, produce effects 2 examples, 0 example that takes a turn for the better, invalid 0 example, cure-remarkable-effectiveness rate 100%.Two groups of medicines are all effective, and of the present invention group the most remarkable, and cure-remarkable-effectiveness rate can reach 100%.
The table 1 liang schizoid curative effect of group Drug therapy relatively
| Group | n | Recovery from illness | Produce effects | Take a turn for the better | Invalid | Cure-remarkable-effectiveness rate (%) |
| Matched group | 30 | 21 | 4 | 5 | 0 | 83.3 |
| Of the present invention group | 30 | 28 | 2 | 0 | 0 | 100 |
Different time BPRS scoring, BPRS subtract the branch rate and the results are shown in Table 2 before and after two groups of Drug therapys, and table 2 is comparisons that two groups of Drug therapys front and back different time BPRS scorings and BPRS subtract the branch rate.By table 2 data as seen: BPRS scoring: significantly descend (P＜0.01) before two groups for the treatment of backs and the treatment, all and 8 of the present invention group falls when all for the treatment of 4 all significantly are better than matched group (P＜0.05); BPRS subtracts the branch rate: when 4 weeks for the treatment of and 8 weeks, of the present invention group significantly is better than matched group (P＜0.05).
Different time BPRS scoring and BPRS subtract the comparison (x ± s) of branch rate before and after the table 2 liang group Drug therapy
Annotate: * * P＜0.01, relatively preceding with the treatment of this group;
+Compare with the concurrent control group P＜0.05.
Two groups of adverse reactions of patients (TESS) compare: matched group untoward reaction person is totally 4 examples, slight dizzy 2 examples, abdominal distention 2 examples; Group untoward reaction person of the present invention is totally 1 example, and slight dizzy 1 example after suitably adjusting dosage, is obviously alleviated.Two groups of patients there is no hemogram and hepatic and renal function injure.Of the present invention group of untoward reaction situation is starkly lower than matched group (P＜0.05).
The above only is preferred implementation of the present invention; should be pointed out that for those skilled in the art, under the prerequisite that does not break away from the inventive method; can also make some improvement and replenish, these improvement and replenish and also should be considered as protection scope of the present invention.
Claims (2)
1. the application of Chinese medicine in preparation treatment paranoid schizophrenia medicine, described Chinese medicine is to be made by following bulk drugs: Fructus Psoraleae 10-16 part, Herba Asari 6-9 part, Semen Persicae 5-8 part, Fructus Aurantii 2-5 part, Semen Sojae Preparatum 2-5 part.
2. require 1 described application as requested, described Chinese medicine is to be made by following bulk drugs: 13 parts of Fructus Psoraleaes, 8 parts of Herba Asaris, 6 parts in Semen Persicae, 3 parts of Fructus Aurantiis, 3 parts of Semen Sojae Preparatums.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310193209XA CN103263513A (en) | 2013-05-23 | 2013-05-23 | Application of traditional Chinese medicine in preparation of drugs for paranoid psychosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310193209XA CN103263513A (en) | 2013-05-23 | 2013-05-23 | Application of traditional Chinese medicine in preparation of drugs for paranoid psychosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103263513A true CN103263513A (en) | 2013-08-28 |
Family
ID=49007207
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310193209XA Pending CN103263513A (en) | 2013-05-23 | 2013-05-23 | Application of traditional Chinese medicine in preparation of drugs for paranoid psychosis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103263513A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101088498A (en) * | 2006-06-13 | 2007-12-19 | 和泓生物技术（上海）有限公司 | Application of bakuchiol compound |
-
2013
- 2013-05-23 CN CN201310193209XA patent/CN103263513A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101088498A (en) * | 2006-06-13 | 2007-12-19 | 和泓生物技术（上海）有限公司 | Application of bakuchiol compound |
Non-Patent Citations (6)
| Title |
|---|
| 万红娇等: "《中医药治疗精神分裂症的临床研究概况》", 《江西中医学院学报》, vol. 21, no. 5, 31 October 2009 (2009-10-31), pages 92 - 95 * |
| 崔林华等: "精神分裂症中医络病学发病阐释及针灸选穴方法", 《中国中医药信息杂志》, vol. 15, no. 12, 31 December 2008 (2008-12-31), pages 99 - 100 * |
| 李玉欣等: "中药配合抗精神病药物维思通治疗首发精神分裂症临床对照研究", 《精神疾病与精神卫生》, vol. 4, no. 4, 31 December 2004 (2004-12-31) * |
| 罗万英: "《"四神汤"原方致精神分裂1例》", 《陕西中医学院学报》, vol. 20, no. 1, 31 December 1997 (1997-12-31), pages 40 * |
| 谷朝阳等: "大豆甙元磺酸钠抗抑郁作用的研究", 《陕西师范大学学报(自然科学版)》, vol. 34, no. 3, 30 September 2006 (2006-09-30), pages 92 - 96 * |
| 边洪昌: "《中医辨治精神分裂症208例》", 《河南中医》, vol. 23, no. 4, 30 April 2003 (2003-04-30), pages 31 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103230506A (en) | Bone-setting medicament | |
| CN102631579A (en) | Oral Chinese herbal preparation for treating post-traumatic brain syndrome | |
| CN102258742B (en) | Chinese medicinal medicine composition for treating depression and preparation method thereof | |
| CN103585561B (en) | A kind of Chinese medicine composition for the treatment of gout | |
| CN103316110A (en) | Use of medicine in simple schizophrenia treatment medicines | |
| CN103405719A (en) | Medicament for treatment of depression | |
| CN102526645B (en) | Medicament for treating dysthymic disorder | |
| CN103316111A (en) | Application of medicine in preparation of hebephrenic schizophrenia treatment medicines | |
| CN103316126A (en) | Traditional Chinese medicine for treating schizophrenia | |
| CN103263513A (en) | Application of traditional Chinese medicine in preparation of drugs for paranoid psychosis | |
| CN103550702A (en) | Traditional Chinese medicine composition for cerebral arterial thrombosis | |
| CN103263506A (en) | Application of medicine in preparation of drugs for paranoid psychosis | |
| CN103263505A (en) | Medicine for treating schizophrenia | |
| CN103479970A (en) | External medicine for treating rheumatic arthralgia | |
| CN103655849B (en) | Chinese medicine composition for the treatment of anemofrigid cold and its preparation method and application | |
| CN104288684A (en) | Medicinal composition for treating schizophrenia | |
| CN103784893B (en) | A kind of medicine for the treatment of cerebral apoplexy sequela | |
| CN103599265B (en) | A kind of compound traditional Chinese medicine for radiation protection | |
| CN103316109A (en) | Use of medicine in catatonic schizophrenia treatment medicines | |
| CN103316125A (en) | Use of traditional Chinese medicine in preparation of hebephrenic schizophrenia treatment medicines | |
| CN103316127A (en) | Use of traditional Chinese medicine in catatonic schizophrenia treatment medicines | |
| CN103385956A (en) | Application of traditional Chinese medicine in preparation of drug used for treating simple schizophrenia | |
| CN104474173B (en) | A kind of medicine for treating facioplegia | |
| CN103386080B (en) | Medicine composite for curing combined external head injuries in clinical nursing | |
| CN102416147B (en) | Medicinal composition for treating mania of patients abstained from drugs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20130828 |